Little Response of Cerebral Metastasis from Hepatocellular Carcinoma to Any Treatments.
10.3340/jkns.2010.47.5.325
- Author:
Jung Ho HAN
1
;
Dong Gyu KIM
;
Jung Cheol PARK
;
Hyun Tai CHUNG
;
Sun Ha PAEK
;
Young Seob CHUNG
Author Information
1. Department of Neurosurgery, Seoul National University Bundang Hospital, Seongnam, Korea.
- Publication Type:Original Article
- Keywords:
Brain metastasis;
Hepatocellular carcinoma;
Survival outcome;
Prognostic factor
- MeSH:
Brain;
Carcinoma, Hepatocellular;
Cerebral Hemorrhage;
Disease-Free Survival;
Humans;
Male;
Neoplasm Metastasis;
Retrospective Studies;
Survival Rate
- From:Journal of Korean Neurosurgical Society
2010;47(5):325-331
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: We retrospectively evaluated the survival outcome of patients with brain metastasis from hepatocellular carcinoma (HCC). METHODS: Between 1991 and 2007, a total of 20 patients were diagnosed as having brain metastasis from HCC. The mean age of the patients was 55 +/- 13 years, and 17 (85.0%) were men. Seventeen (85.0%) patients had already extracranial metastases. The median time from diagnosis of HCC to brain metastasis was 18.5 months. Fourteen (70.0%) patients had stroke-like presentation due to intracerebral hemorrhage (ICH). Ten (50.0%) patients had single or solitary brain metastasis. Among a total of 34 brain lesions, 31 (91.2%) lesions had the hemorrhagic components. RESULTS: The median survival time was 8 weeks (95% CI, 5.08-10.92), and the actuarial survival rates were 85.0%, 45.0%, 22.5%, and 8.4% at 4, 12, 24, and 54 weeks. Age < 60 years, treatment of the primary and/or extracranial lesions, and recurrent ICH were the possible prognostic factors (p = 0.044, p < 0.001, and p = 0.111, respectively). The median progression-free survival (PFS) time was 3 months (95% CI, 0.95-5.05). CONCLUSION: The overall survival of the patients with brain metastasis from HCC was very poor with median survival time being only 8 weeks. However, the younger patients less than 60 years and/or no extracranial metastases seem to be a positive prognostic factor.
